Conference Coverage

VIDEO: Encouraging results reported for novel Huntington’s disease therapy


 

REPORTING FROM AAN 2018


The clinical results are exploratory and require confirmation in larger studies, Dr. Tabrizi stressed.

The study was supported by Ionis Pharmaceuticals. Roche will develop the drug in further clinical trials.

SOURCE: Tabrizi S et al. AAN 2018 abstract CT.002.

Pages

Recommended Reading

Mass Psychogenic Illness: Risk Factors and Treatment
MDedge Neurology
Mogamulizumab active in HTLV-1–associated myelopathy
MDedge Neurology
New Drug Technology Could Treat Huntington’s Disease
MDedge Neurology
Gait freezing relieved by spinal cord, transcranial direct-current stimulation
MDedge Neurology
25 Years of Movement Disorders
MDedge Neurology
Tear proteins seen as Parkinson’s biomarker
MDedge Neurology
Low vitamin B12 tied to worsening mobility, cognition in early Parkinson’s
MDedge Neurology
Office-based screen predicts dementia in Parkinson’s disease
MDedge Neurology
Distinguish neurogenic from nonneurogenic orthostatic hypotension
MDedge Neurology
MDedge Daily News: Could gut bacteria trigger lupus?
MDedge Neurology